Tags

Type your tag names separated by a space and hit enter

Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis.
Curr Med Res Opin. 2020 11; 36(11):1861-1872.CM

Abstract

OBJECTIVE

Fractures due to osteoporosis represent a serious burden on patients and healthcare systems. The objective of this review is to provide an overview of the anabolic agent abaloparatide (ABL) for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

METHODS

A literature review was conducted using PubMed to identify articles focused on ABL published prior to February 10, 2020, using the search term "abaloparatide".

RESULTS

ABL, a synthetic analog of human parathyroid hormone-related protein, increased bone mineral density (BMD), improved bone microarchitecture, and increased bone strength in preclinical and clinical studies. The pivotal phase 3 trial ACTIVE and its extension (ACTIVExtend) demonstrated the efficacy of initial treatment with ABL for 18 months followed by sequential treatment with alendronate (ALN) for an additional 24 months to reduce the risk of vertebral, nonvertebral, clinical, and major osteoporotic fractures and to increase BMD in postmenopausal women with osteoporosis. Discontinuations from ACTIVE were slightly more common in ABL-treated patients due to dizziness, palpitations, nausea, and headache. Post hoc analyses of ACTIVE and ACTIVExtend support the efficacy and safety of ABL in relevant subpopulations including postmenopausal women with various baseline risk factors, women ≥80 years, women with type 2 diabetes mellitus, and women with renal impairment.

CONCLUSIONS

ABL is an effective and well-tolerated treatment for women with postmenopausal osteoporosis at high risk for fracture. Its therapeutic effects are sustained with subsequent ALN therapy.

Authors+Show Affiliations

Colorado Center for Bone Research, Denver, CO, USA. Colorado Center for Bone Health, Golden, CO, USA.Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.Radius Health, Inc., Waltham, MA, USA.Radius Health, Inc., Waltham, MA, USA.Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA.Michigan Bone and Mineral Clinic, P.C., Detroit, MI, USA. Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

32969719

Citation

Miller, Paul D., et al. "Abaloparatide: an Anabolic Treatment to Reduce Fracture Risk in Postmenopausal Women With Osteoporosis." Current Medical Research and Opinion, vol. 36, no. 11, 2020, pp. 1861-1872.
Miller PD, Bilezikian JP, Fitzpatrick LA, et al. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. Curr Med Res Opin. 2020;36(11):1861-1872.
Miller, P. D., Bilezikian, J. P., Fitzpatrick, L. A., Mitlak, B., McCloskey, E. V., Cosman, F., & Bone, H. G. (2020). Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. Current Medical Research and Opinion, 36(11), 1861-1872. https://doi.org/10.1080/03007995.2020.1824897
Miller PD, et al. Abaloparatide: an Anabolic Treatment to Reduce Fracture Risk in Postmenopausal Women With Osteoporosis. Curr Med Res Opin. 2020;36(11):1861-1872. PubMed PMID: 32969719.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. AU - Miller,Paul D, AU - Bilezikian,John P, AU - Fitzpatrick,Lorraine A, AU - Mitlak,Bruce, AU - McCloskey,Eugene V, AU - Cosman,Felicia, AU - Bone,Henry G, Y1 - 2020/10/12/ PY - 2020/9/25/pubmed PY - 2021/6/29/medline PY - 2020/9/24/entrez KW - Abaloparatide KW - anabolic KW - nonvertebral fracture KW - osteoporosis KW - vertebral fracture SP - 1861 EP - 1872 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 36 IS - 11 N2 - OBJECTIVE: Fractures due to osteoporosis represent a serious burden on patients and healthcare systems. The objective of this review is to provide an overview of the anabolic agent abaloparatide (ABL) for the treatment of postmenopausal women with osteoporosis at high risk for fracture. METHODS: A literature review was conducted using PubMed to identify articles focused on ABL published prior to February 10, 2020, using the search term "abaloparatide". RESULTS: ABL, a synthetic analog of human parathyroid hormone-related protein, increased bone mineral density (BMD), improved bone microarchitecture, and increased bone strength in preclinical and clinical studies. The pivotal phase 3 trial ACTIVE and its extension (ACTIVExtend) demonstrated the efficacy of initial treatment with ABL for 18 months followed by sequential treatment with alendronate (ALN) for an additional 24 months to reduce the risk of vertebral, nonvertebral, clinical, and major osteoporotic fractures and to increase BMD in postmenopausal women with osteoporosis. Discontinuations from ACTIVE were slightly more common in ABL-treated patients due to dizziness, palpitations, nausea, and headache. Post hoc analyses of ACTIVE and ACTIVExtend support the efficacy and safety of ABL in relevant subpopulations including postmenopausal women with various baseline risk factors, women ≥80 years, women with type 2 diabetes mellitus, and women with renal impairment. CONCLUSIONS: ABL is an effective and well-tolerated treatment for women with postmenopausal osteoporosis at high risk for fracture. Its therapeutic effects are sustained with subsequent ALN therapy. SN - 1473-4877 UR - https://www.unboundmedicine.com/medline/citation/32969719/Abaloparatide:_an_anabolic_treatment_to_reduce_fracture_risk_in_postmenopausal_women_with_osteoporosis_ L2 - https://www.tandfonline.com/doi/full/10.1080/03007995.2020.1824897 DB - PRIME DP - Unbound Medicine ER -